Market Overview

The nano-biosensors market is expected to register a CAGR of 10%, during the forecast period 2020-2025. The trend in the adoption of smart technologies with the size of devices decreasing will drive the nano-biosensors market in the forecast period.

  • Despite the economic stagnancy in most of the regions, advanced technologies have always been the driving force of new opportunities and further development. Constant R&D on new technologies, namely nanotechnology, can bring market advantage for innovative companies.
  • Continuous development in nanotechnology tools and gaining insights into nanoscale phenomena are expected to be crucial for improving the performance of existing nanosensors and support researchers in the development of nanosensors based on innovative mechanisms.
  • UBI with Siemens Healthcare Diagnostics manufacture three test strips for the professional point-of-care coagulation testing. The product PT/INR launched in December 2014 used for the patients to self diagnose themselves, in terms of glucose level, blood pressure, etc. Which gives professionals results. This coagulation testing is estimated to be worth about US$1 billion and growing at ~10% per year. In this market.
  • The major challenge for the nano-biosensors would be its operation. Since these machines are digital, the readings are very accurate and understanding them could be a challenge for the patients.



Scope of the Report

A nano-biosensor is a sensing device made up of nanomaterials that can detect the presence of a chemical substance that combines a biological component with a physicochemical detector via biological interactions. The applications for nano-biosensor lands at food quality estimation, environmental monitoring, consumer electronics, and diagnosis of clinical and metabolic complications.

Key Market Trends

Healthcare Industry Holds the Significant Share in the Market

  • The growth of the healthcare segment can be primarily attributed to the use of nanosensors in medical diagnostics to detect cancers, measure the actual glucose level for diabetes, or as blood-borne sensors.
  • According to the United Nation’s Millennium Development Goals, the 21st century is facing a significant threat due to an increase in diabetes which is the primary cause of non-traumatic amputation and blindness in developed countries to their health and economic development. In 2013, 380 million people had diabetes, and approximately 600 million people to still have it by 2035.
  • The nano biosensor is used as an indicator of diabetes, and for its cure there has to be a proper food intake which is also taken care of nano biosensor to check the quality of food, the enzyme-based electrode is studied because of their high selectivity and sensitivity. Due to which it has drives the healthcare industry over the forecast period.



North America Dominates the Market

  • Owing to consistent innovations and investments in R&D of nanosensors to appeal to a wide consumer base, and have led to several technological advancements in this market.
  • However, the Asia-Pacific region is expected to record growth with the highest CAGR, due to the improved therapies that are based on nanosensors. China is expected to lead this extraordinary growth in Asia-Pacific, due to ongoing technological up gradation in the healthcare and biomedical segments.
  • Furthermore, with the rising significance of intelligent packaging, adoption of nanosensors is expected to witness a considerable increase. Nanotechnology, nano minerals, and nanosensors in the agri-food sector, including feed and nutrient components, intelligent packaging, and quick detection systems, can be seen as the new sources of key improvements in the agricultural sector.
  • Nanosensors are in high demand in the homeland security and military industries as they are used for the detection of radiations and biotoxins. They also have benefited the military by helping in the development of advanced Warfield gear, such as lighter vehicles and self-repairing tents.



Competitive Landscape

The major players include - Abbott Point of Care, Inc., Medtronic Inc., Siemens AG, Lifescan, Inc., Lifesensors, Inc., Nova Biomedical, ACON Laboratories, Inc., STMicroelectronics, and Bayer Healthcare AG, among others. The market is neither fragmented nor consolidated since there is no competition between major players. Hence, the market concentration will be moderate.

  • January 2018 - The researchers created a biosensor using nanoribbons of indium oxide, an enzyme glucose oxidase, a natural chitosan film, and single-walled carbon nanotubes. When glucose is present in a test sample, it interacts with the enzyme, setting off a short chain of reactions and ultimately creating an electrical signal. Testing showed that the device could detect a range of glucose concentrations from 10 nanomolar to 1 millimolar, which is sensitive enough to cover typical glucose levels in sweat, saliva and tears in people with and without diabetes. Bending the film 100 times didn’t noticeably affect its performance. In addition to glucose tracking, the researchers suggest that the sensor could also be used for monitoring in the food and environmental sectors.



Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client’s requirements
  • 3 months of analyst support